Olverembatinib for FGFR1-rearranged Neoplasms
A Study of Olverembatinib in the Treatment of Myeloid/Lymphoid Tumors With FGFR1 Rearrangement
The First Affiliated Hospital of Soochow University
20 participants
Sep 1, 2022
INTERVENTIONAL
Conditions
Summary
FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic hematopoietic stem cell transplantation (HSCT) in remission. This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.
Eligibility
Inclusion Criteria4
- Patients with newly diagnosed, progressed or relapsed myeloid/lymphoid neoplasms with FGFR1 rearrangement according to the WHO-2016 diagnostic criteria. Patients who have received allogeneic hematopoietic stem cell transplantation or ponatinib should be excluded.
- ECOG score: MPNs patients, 0-3 points; AL patients, 0-2 points.
- Expected survival period ≥12 weeks.
- Willingness and ability to comply with study procedures and follow-up examination.
Exclusion Criteria5
- Patients who have received allogeneic hematopoietic stem cell or ponatinib.
- Human immunodeficiency virus (HIV) infection, or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive).
- Patients who are pregnant, planning to become pregnant or breastfeeding.
- Patients who may not be able to complete all study visits or procedures required by the study protocol, including follow-up visits, and/or fail to comply with all required study procedures.
- Patients who suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the research drug.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Given PO
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05521204